Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05977673 |
| Title | Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy: a Phase II, Open-label Study (FIL_Tisle-HL) |
| Acronym | FIL_Tisle-HL |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Fondazione Italiana Linfomi - ETS |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | ITA |